Ken Griffin Novo Cure LTD Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Cure LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 132,800 shares of NVCR stock, worth $2.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
132,800
Previous 120,400
10.3%
Holding current value
$2.2 Million
Previous $1.88 Million
20.89%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding NVCR
# of Institutions
266Shares Held
78.7MCall Options Held
751KPut Options Held
293K-
Black Rock Inc. New York, NY12.1MShares$201 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA11.7MShares$194 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.1MShares$185 Million0.0% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$50.3 Million12.67% of portfolio
-
State Street Corp Boston, MA3.01MShares$49.9 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.74B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...